1. Home
  2. ZTS

as 12-20-2024 3:44pm EST

$
-
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Founded: 1952 Country:
United States
United States
Employees: N/A City: PARSIPPANY
Market Cap: 80.4B IPO Year: 2013
Target Price: $220.33 AVG Volume (30 days): 2.4M
Analyst Decision: Strong Buy Number of Analysts: 9
Dividend Yield:
1.05%
Dividend Payout Frequency: Quarterly
EPS: 5.32 EPS Growth: 8.38
52 Week Low/High: $144.80 - $200.53 Next Earning Date: 02-11-2025
Revenue: $9,152,000,000 Revenue Growth: 9.33%
Revenue Growth (this year): 9.41% Revenue Growth (next year): 4.70%

ZTS Daily Stock ML Predictions

Stock Insider Trading Activity of Zoetis Inc. (ZTS)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Polzer Robert J ZTS Executive Vice President Nov 25 '24 Sell $177.46 3,477 $617,028.42 3,249

Share on Social Networks: